



2026 ASCO
ANNUAL MEETING

#ASCO26

May 29–June 2, 2026

McCormick Place | Chicago, IL & Online
am.asco.org



LucidQuest Intelligence
Accelerate your success

ASCO 2026 Preview – Table of Contents

• <u>New Trends in Oncology Treatment Strategy At ASCO'26</u>	3-5
• <u>Key Sessions To Watch</u>	6
• <u>Industry-sponsored Sessions & Focus Areas At ASCO 2026</u>	7-14
• <u>Competitive Landscape At a Glance at ASCO 2026</u>	8-9
• <u>Key Industry-sponsored Sessions At ASCO 2026</u>	10-14
• <u>New Entrants</u>	15
• <u>AI/ML Trends & Strategic Watchpoints At ASCO 2026</u>	16-19
• <u>AI / DIGITAL HEALTH ANGLE At ASCO 2026</u>	17-19
• <u>What We're Watching For Post-congress</u>	20
• <u>Get In Touch With LucidQuest</u>	21



ASCO 2026 – New Trends in Oncology Treatment Strategy (1/3)



• **NSCLC targeted therapy will face earlier-line and sequencing pressure**

- ASCO 2026 will include LIBRETTO-432 adjuvant selpercatinib, WU-KONG28 sunvozertinib, pralsetinib in AcceleRET-Lung, and lorlatinib CROWN 7-year follow-up, spanning RET fusion-positive, EGFR exon20ins, and ALK-positive NSCLC. The strategic question will be whether these biomarker-directed agents can move earlier in treatment while preserving clear sequencing logic, especially as more targeted options compete for frontline or adjuvant positioning



• **Squamous NSCLC will test PD-1/VEGF bispecific differentiation**

- The HARMONi-6 plenary will compare ivonescimab + chemotherapy with tislelizumab + chemotherapy in previously untreated advanced squamous NSCLC, creating a direct test of PD-1/VEGF bispecific biology against a PD-1 chemotherapy backbone. The competitive tension will be whether dual immune and angiogenesis targeting can deliver enough clinical differentiation to challenge established checkpoint chemotherapy standards



ASCO 2026 – New Trends in Oncology Treatment Strategy (2/3)



• **Breast cancer competition will center on ADCs and endocrine resistance**

- ASCO 2026 will feature ASCENT-04 sacituzumab govitecan + pembrolizumab, TROPION-Breast02 datopotamab deruxtecan, DESTINY-Breast07 T-DXd + durvalumab, imlunestran, and abemaciclib. The unresolved question will be whether these data clarify sequencing in TNBC and HR+/HER2– disease or add more parallel options without a clear treatment hierarchy



• **GU oncology will balance intensification with long-term treatment burden**

- The PROTEUS plenary will test apalutamide + ADT in high-risk localized/locally advanced prostate cancer, while EV-302 will provide longer follow-up for enfortumab vedotin + pembrolizumab in urothelial cancer. PSMA radioligand sessions with 225Ac-PSMA-617, Ac-225 rosopatomab tetraxetan, and 177Lu-PSMA-617 will keep sequencing pressure high





- **GI oncology will pressure-test RAS targeting and ctDNA-guided decisions**

- The RASolute 302 plenary will evaluate daraxonrasib versus chemotherapy in metastatic pancreatic adenocarcinoma. Additional sessions on sotorasib + panitumumab, CIRCULATE, and GALAXY ctDNA will test whether molecular diagnostics can guide treatment, not just risk stratification



- **AI and digital oncology tools will remain workflow-focused rather than asset-defining**

- ASCO 2026 will include THRIVE-MM, LLM-generated serious illness conversation summaries, AI-generated patient education, and the “Oncology 2.0” AI symposium. The strategic question will be whether these tools show measurable clinical workflow or patient-management value beyond pilot-stage implementation

Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
29 May 2026	WU-KONG28: sunvozertinib vs platinum chemotherapy	Oral Abstract Session	John V. Heymach / MD Anderson	Could define frontline expectations in EGFR exon20ins NSCLC
29 May 2026	EV-302: EV + pembrolizumab 3.5-year follow-up	Oral Abstract Session	Thomas Powles / Queen Mary, University of London	Longer follow-up will test durability of EV + pembrolizumab in untreated Ia/mUC
31 May 2026	PROTEUS: apalutamide + ADT in high-risk prostate cancer	Plenary Session	Mary-Ellen Taplin / Dana-Farber Cancer Institute	Tests whether perioperative androgen-axis intensification can change localized high-risk prostate cancer management
31 May 2026	SARC041: abemaciclib in dedifferentiated liposarcoma	Plenary Session	Mark A. Dickson / MSK	A rare sarcoma Phase 3 readout that may define whether CDK4/6 inhibition has a role beyond breast cancer
31 May 2026	LIBRETTO-432: adjuvant selpercatinib in RET+ NSCLC	Plenary Session	Jonathan W. Goldman	Tests whether RET inhibition can move into early-stage NSCLC with event-free survival impact
31 May 2026	HARMONi-6: ivonescimab + chemotherapy in squamous NSCLC	Plenary Session	Shun Lu / Shanghai Chest Hospital	Directly challenges PD-1 chemotherapy standards using a PD-1/VEGF bispecific approach
31 May 2026	RASolute 302: daraxonrasib vs chemotherapy in mPDAC	Plenary Session	Brian M. Wolpin / Dana-Farber GI Cancer Center	A pivotal test of RAS(ON) inhibition in pancreatic cancer against chemotherapy
02 June 2026	TROPION-Breast02: Dato-DXd vs chemotherapy in TNBC	Oral Abstract Session	David W. Cescon / Princess Margaret-University Health Network	Tests Dato-DXd's role in first-line TNBC where immunotherapy is not an option

Industry-Sponsored Sessions & Focus Areas – ASCO 2026





ASCO 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
NSCLC targeted therapy and frontline combinations	Multiple	Selpercatinib, sunvozertinib, pralsetinib, lorlatinib, ivonescimab, tislelizumab, amivantamab + lazertinib	NSCLC remains a major battleground where molecular segmentation and IO-combination strategy will compete for earlier-line positioning
Breast cancer ADCs and endocrine-resistance strategies	Multiple	Sacituzumab govitecan, datopotamab deruxtecan, trastuzumab deruxtecan, imlunestrant, abemaciclib, capivasertib	Breast cancer sessions will test whether ADCs and endocrine-resistance regimens clarify sequencing or add more parallel options
GU oncology escalation and radioligands	Multiple	Apalutamide, enfortumab vedotin + pembrolizumab, durvalumab, 177Lu-PSMA-617, 225Ac-PSMA-617, Ac-225 rosopatamab tetraxetan	GU oncology will test how far earlier intensification and radioligand strategies can move before toxicity, access, and sequencing constraints become limiting
Hematologic malignancies and plasma cell disorders	Multiple	Linvoseltamab, belantamab mafodotin, mezigdomide, odronextamab, golcadomide, BCMA-directed strategies	Hematology sessions will test whether bispecifics, CELMoDs, and BCMA-directed approaches can move earlier while preserving sequencing flexibility



ASCO 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
GI targeted therapy, ctDNA, and MCED	Multiple	Daraxonrasib, sotorasib + panitumumab, CIRCULATE, GALAXY, ctDNA, MCED	GI oncology will pressure-test whether targeted therapy and diagnostics can guide treatment decisions, not only stratify patients
ADC platform expansion beyond core tumor types	Multiple	BAT8008, CRB-701/SYS6002, YL201, TROP-2 ADCs, Nectin-4 ADCs, B7-H3 ADCs	ADC sessions will test whether newer targets and payload platforms can generate meaningful activity beyond established breast and urothelial cancer settings
AI, digital health, MRD, and ctDNA-enabled care	Multiple	THRIVE-MM, LLM summaries, AI education tools, Precise MRD, Oncodetect, ctDNA, MCED	The adoption question is whether diagnostics and digital tools change workflows and treatment decisions rather than remaining validation-stage evidence



Key Industry-Sponsored Sessions at ASCO 2026 (1/5)

- **BMS:**

- Focus Areas: RRMM & Emerging CELMoD Research
- Sessions will address evolving treatment needs in relapsed/refractory multiple myeloma and position CELMoD research as a potential differentiation area in later-line disease

- **Eli Lilly:**

- Focus Areas: ER+/HER2– Breast Cancer, Oral SERD Therapy & CDK4/6 Inhibition
- Presentations will focus on Inluriyo™ (imlunestrant) and Verzenio® (abemaciclib), with emphasis on endocrine-resistance management and sequencing in advanced or metastatic breast cancer

- **Bayer:**

- Focus Areas: HER2-Mutant NSCLC & Sevabertinib Development
- Highlight will be on HYRNUO® (sevabertinib) from translational rationale to clinical application in HER2-mutant lung cancer carcinoma



Key Industry-Sponsored Sessions at ASCO 2026 (2/5)



- **Johnson & Johnson:**

- Focus Areas: Oncology Strategy & RRMM Combination Therapy
- Sessions will signal broader oncology ambition through cancer elimination messaging and a 2L+ RRMM combination therapy after prior proteasome inhibitor and immunomodulatory-agent exposure



- **Tempus:**

- Focus Areas: AI, Diagnostic Insights & Foundation Models
- Presentations will position AI-enabled diagnostics and foundation models as tools to support oncology decision-making, patient identification, and data-driven care pathways



- **GSK:**

- Focus Areas: Multiple Myeloma Treatment Options
- Sessions will reinforce GSK's focus on multiple myeloma through product-level education for patients with plasma cell malignancies



Key Industry-Sponsored Sessions at ASCO 2026 (3/5)



- **Myriad Genetics:**

- Focus Areas: MRD Detection & Recurrence Monitoring
- Sessions will position Precise MRD™ as an ultra-sensitive molecular residual disease detection tool for recurrence monitoring and biomarker-informed oncology care



- **Cogent Biosciences:**

- Focus Areas: Advanced GIST & Phase 3 PEAK Evidence
- Topics will be on efficacy and safety data from the Phase 3 PEAK study in advanced gastrointestinal stromal tumors



- **GRAIL:**

- Focus Areas: MCED Testing & Earlier Cancer Diagnosis
- Sessions will focus on multi-cancer early detection and its potential role in shifting diagnosis toward earlier-stage cancer identification



Key Industry-Sponsored Sessions at ASCO 2026 (4/5)

- **Abbott / Exact Sciences:**

- Focus Areas: MRD Detection & Oncodetect® Evidence
- Presentations will showcase analytical and clinical evidence supporting the Oncodetect® MRD test for post-treatment surveillance and molecular recurrence detection

- **Merck & Co.:**

- Focus Areas: Subcutaneous Immunotherapy & Treatment Delivery
- Topics will address an immunotherapy treatment option administered subcutaneously, with emphasis on administration convenience and care-delivery efficiency

- **AbbVie:**

- Focus Areas: 1L CLL, BCL-2 Inhibition & Fixed-Duration Therapy
- Sessions will cover a BCL-2 inhibitor–based combination therapy in first-line CLL, with emphasis on targeted fixed-duration treatment and time off therapy





Key Industry-Sponsored Sessions at ASCO 2026 (5/5)

- **Daiichi Sankyo and AstraZeneca:**

- Focus Areas: HER2-Expressing Breast Cancer, EGFR-Mutated NSCLC & HR+/HER2- mBC
- Sessions will focus on treatment strategies across HER2-expressing breast cancer, EGFR-mutated NSCLC, and HR+/HER2- metastatic breast cancer with HER2-low or HER2-ultralow expression

- **AstraZeneca:**

- Focus Areas: HR+/HER2- Breast Cancer, Gastric/GEJ Cancer & HCC
- Sessions will emphasize TRUQAP + fulvestrant in biomarker-selected HR+/HER2- advanced breast cancer, alongside treatment approaches in resectable gastric/GEJ cancers and unresectable hepatocellular carcinoma



New Entrants

Asset / Company	2026 Presence
IMA401	Oral Abstract Session: First-in-human MAGEA4/8-targeted TCR-based bispecific T-cell engager in recurrent/refractory solid tumors
DXC006	Oral Abstract Session: DXC006, a first-in-class CD56-targeting antibody-drug conjugate, in advanced solid tumors: A first-in-human, phase I dose escalation clinical trial
SYS6043	Oral Abstract Session: First-in-human study of SYS6043, a novel B7-H3-targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies
RNK08954	Oral Abstract Session: Clinical activity and safety of RNK08954 in advanced non-small cell lung cancer (NSCLC) patients with KRAS G12D mutation
DN022150	Oral Abstract Session: Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D-mutant solid tumors.
HR20013	Oral Abstract Session: Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Chiauranib	Oral Abstract Session: A phase III CHIPRO study of chiauranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer
Anselamimab	Oral Abstract Session: Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis





AI/ML Trends & Strategic Watchpoints at ASCO 2026





AI / Digital Health Angle at ASCO 2026 (1/3)

- **AI and digital-health presentations at ASCO 2026 represent an oncology workflow and decision-support signal, not a generic digital-health theme. The concentration of sessions focused on AI-generated patient education, LLM-supported serious illness communication, digital psychosocial support, remote oncology, screening triage, computational histology, and EHR-based cancer risk prediction suggests these tools are being tested where they could influence patient communication, care navigation, treatment selection, screening workflows, and clinician workload**
- **AI/ML activity at ASCO 2026 is strategically relevant because it is focused on how oncology teams manage information complexity across diagnosis, treatment planning, and longitudinal care, rather than AI-enabled drug discovery. The most important signal is whether these tools can move from validation or pilot use into workflows that affect treatment decisions, patient support, risk stratification, and care delivery efficiency**
- **Key sessions include:**
 - Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma
 - LLM-generated serious illness conversation summaries to improve care for hospitalized patients: A pilot clinical trial



AI / Digital Health Angle at ASCO 2026 (2/3)

- The Bot Will See You Now: Evaluating Artificial Intelligence-Generated Patient Education
- Oncology 2.0: How Artificial Intelligence Is Closing the Information Gap—Or Is It?
- Industry Expert Theater: No Patient Left Behind: AI, Diagnostic Insights and Foundation Models that Challenge the Status Quo
- Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer
- Predicting multi-cancer risk from EHR data using multi-agent LLMs
- Telehealth visits to support extended dosing of pembrolizumab and reduce health care visits: A pragmatic trial
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Patient communication through LLM-generated serious illness conversation summaries and AI-generated education tools
 - Psychosocial and supportive care through digital applications such as THRIVE-MM in multiple myeloma
 - Treatment decision support through computational histology models such as CHAI for chemotherapy intensification in metastatic colorectal cancer
 - Cancer risk prediction and screening triage through EHR-based multi-agent LLM models and AI-enabled screening strategies



AI / Digital Health Angle at ASCO 2026 (3/3)

- Remote oncology workflows through telehealth-supported extended dosing and remote care models
- Diagnostic and information infrastructure through foundation models, diagnostic insights, and AI-supported oncology data interpretation



What We're Watching for Post-ASCO 2026

- Whether adjuvant selpercatinib in LIBRETTO-432 generates a strong enough early-stage RET-positive NSCLC signal to support guideline or regulatory momentum beyond metastatic disease
- Whether ivonescimab + chemotherapy in HARMONi-6 demonstrates enough differentiation versus tislelizumab + chemotherapy to challenge established PD-1 chemotherapy standards in frontline squamous NSCLC
- Whether ASCENT-04 sacituzumab govitecan + pembrolizumab and TROPION-Breast02 datopotamab deruxtecan provide clearer sequencing direction for ADC use in first-line TNBC
- Whether PROTEUS apalutamide + ADT shows sufficient perioperative benefit in high-risk localized or locally advanced prostate cancer to justify earlier treatment intensification
- Whether RASolute 302 daraxonrasib delivers clinically meaningful benefit versus chemotherapy in metastatic pancreatic adenocarcinoma, validating RAS(ON) inhibition as a competitive GI oncology strategy
- Whether THRIVE-MM, LLM-generated serious illness summaries, AI-generated patient education, and Oncology 2.0 AI sessions show measurable workflow or patient-management value beyond pilot-stage implementation



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM